Resources
5 Results (showing 1 - 5)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 3/11/2024 (updated 3/28/2024)
This is a resource for harm reduction programs and communities looking to establish new community advisory boards (CABs) or improve upon existing ones. Syringe Services Program Community Advisory Boards: A Framework offers structured recommendations to develop, convene, and sustain effective syringe service program CABs.
Posted 2/29/2024 (updated 3/28/2024)
The 2024 RCORP-Behavioral Health Care Support Onboarding Packet includes resources, tools, and strategies to support grant-funded activities, along with information on accessing TA.
Posted 3/23/2022 (updated 3/27/2024)
Over the past 20 years, drug overdose deaths have increased dramatically in the United States. Most of these deaths involved opioids, including prescription pain medications, heroin, and synthetic opioids such as fentanyl. These are called opioid-related overdoses and often occur as a result of respiratory depression caused by opioids, even when other medications and drugs are involved.
Posted 2/9/2022 (updated 3/26/2024)
Summary of innovation abstracts that were presented at the National Academy of Medicine’s recent Stigma of Addiction Summit.